University of Milano-Bicocca

About: University of Milano-Bicocca is a education organization based out in Milan, Italy. It is known for research contribution in the topics: Population & Blood pressure. The organization has 8972 authors who have published 22322 publications receiving 620484 citations. The organization is also known as: Università degli Studi di Milano-Bicocca & Universita degli Studi di Milano-Bicocca.

Measurement of the $B^0_s \to \mu^+ \mu^-$ branching fraction and search for $B^0 \to \mu^+ \mu^-$ decays at the LHCb experiment

Abstract: A search for the rare decays $B^0_s \to\mu^+\mu^-$ and $B^0 \to\mu^+\mu^-$ is performed at the LHCb experiment. The data analysed correspond to an integrated luminosity of 1 fb$^{-1}$ of $pp$ collisions at a centre-of-mass energy of 7 TeV and 2 fb$^{-1}$ at 8 TeV. An excess of $B^0_s \to\mu^+\mu^-$ signal candidates with respect to the background expectation is seen with a significance of 4.0 standard deviations. A time-integrated branching fraction of ${\cal B}(B^0_s \to\mu^+\mu^-) = (2.9^{+1.1}_{-1.0})\times 10^{-9}$ is obtained and an upper limit of ${\cal B}(B^0 \to\mu^+\mu^-) < 7.4\times 10^{-10}$ at 95% confidence level is set. These results are consistent with the Standard Model expectations.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Abstract: Atypical chronic myeloid leukemia (aCML) shares clinical and laboratory features with CML, but it lacks the BCR-ABL1 fusion. We performed exome sequencing of eight aCMLs and identified somatic alterations of SETBP1 (encoding a p.Gly870Ser alteration) in two cases. Targeted resequencing of 70 aCMLs, 574 diverse hematological malignancies and 344 cancer cell lines identified SETBP1 mutations in 24 cases, including 17 of 70 aCMLs (24.3%; 95% confidence interval (CI) = 16–35%). Most mutations (92%) were located between codons 858 and 871 and were identical to changes seen in individuals with Schinzel-Giedion syndrome. Individuals with mutations had higher white blood cell counts (P = 0.008) and worse prognosis (P = 0.01). The p.Gly870Ser alteration abrogated a site for ubiquitination, and cells exogenously expressing this mutant exhibited higher amounts of SETBP1 and SET protein, lower PP2A activity and higher proliferation rates relative to those expressing the wild-type protein. In summary, mutated SETBP1 represents a newly discovered oncogene present in aCML and closely related diseases.

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

Abstract: Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance' The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols